Lucid Capital initiated coverage of Atai Life Sciences (ATAI) with a Buy rating and $12 price target Atai has assembled one of the largest drug portfolios in “seven short years,” including four psychedelic programs, to revolutionize the treatment of mental health, the analyst tells investors in a research note. The firm views the company as an “aspiring leader” in mental health.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- ATAI Life Sciences and Beckley Psytech Merger: Strategic Moves and Promising Pipeline Justify Buy Rating
- Psychedelic: atai, Beckly Psytech to combine in all-share transaction
- Strategic Acquisition and Promising Data Boost ATAI Life Sciences’ Buy Rating
- Strategic Merger and Financial Strength Propel ATAI Life Sciences to ‘Buy’ Rating
- ATAI Life Sciences Announces Share Purchase Agreement